Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):304–310. doi: 10.1097/QAI.0000000000002028

Figure 2.

Figure 2.

The estimated proportion of women who were nonadherent based on plasma dapivirine (DPV) levels, by baseline general ring worry (RW) and enrollment pre-/post adherence monitoring intervention among women using a dapivirine ring in the ASPIRE trial (N=1,270). Estimates are from mixed-effect logistic regression model adjusting for age group, country, and time in study.